Total Funding
29
4
Total FundingConvertible Note raised
Growth Score
-3 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
515998
Icon Bioscience develops and commercializes novel ophthalmic pharmaceuticals through a proprietary drug delivery platform.
Acquired by 
EyePoint Pharmaceuticals
Vernon G. Wong: Chairman/Founder- William S.White: CEO
About the Company
IBI is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market. IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase
2/3 clinical trial, in December 2012. An NDA is planned for late 2013.
It was founded in 2004 and headquartered in Sunnyvale, California.
